We investigated hyperpolarized (HP) [2-13C]pyruvate conversion to [2-13C]lactate and [5-13C]glutamate for the first time in the healthy human brain, with a focus on the development of hyperpolarization and preparation techniques for sterile [2-13C]pyruvate with FDA-IND & IRB approval. HP [2-13C]pyruvate, [2-13C]lactate, [5-13C]glutamate and other metabolites were successfully observed and quantitatively measured for the first time in four volunteers, and initial EPI studies confirmed a feasibility of imaging [2-13C]pyruvate to [5-13C]glutamate conversion, demonstrating a significant first step for HP metabolic imaging to diagnose and detect early stage neurological disorders.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords